Citations

Clear

6273 citation(s) found for "To, Andrew".

Pneumocystis jirovecii Rtt109, a Novel Drug Target for Pneumocystis Pneumonia in Immunosuppressed Humans
Dahlin, Jayme L. , Han, Junhong , Zhou, Hui , Zhang, Zhiguo , Kottom, Theodore, Kottom, Theodore J. , Walters, Michael A. , Zhang, Zhiguo , Limper, Andrew H. , Zhang, Zhiguo

Mayo Clinic

Antimicrobial Agents and Chemotherapy | April 15, 2014 | Volume: 58 | Issue: 7 | Pages: 3650-3659

10.1128/aac.02637-14 | PMID 24733475 Get It

ABSTRACT Pneumocystis pneumonia (PcP) is a significant cause of morbidity and mortality in immunocompromised patients. In humans, PcP is caused by the opportunistic fungal species Pneumocystis jirovecii . Progress in Pneumocystis research has been hampered by a lack of viable in vitro culture methods, which limits laboratory access to human-derived organisms for drug testing. Consequently, most basic drug discovery research for P. jirovecii is performed using related surrogate organisms such as Pneumocystis carinii , which is derived from immunosuppressed rodents. While these studies provide useful insights, important questions arise about interspecies variations and the relative utility of identified anti- Pneumocystis agents against human P. jirovecii . Our recent work has identified the histone acetyltransferase (HAT) Rtt109 in P. carinii (i.e., PcRtt109) as a potential therapeutic target for PcP, since Rtt109 HATs are widely conserved in fungi but are absent in humans. To further address the potential utility of this target in human disease, we now demonstrate the presence of a functional Rtt109 orthologue in the clinically relevant fungal pathogen P. jirovecii (i.e., PjRtt109). In a fashion similar to that of Pcrtt109 , Pjrtt109 restores H3K56 acetylation and genotoxic resistance in rtt109 -null yeast. Recombinant PjRtt109 is an active HAT in vitro , with activity comparable to that of PcRtt109 and yeast Rtt109. PjRtt109 HAT activity is also enhanced by the histone chaperone Asf1 in vitro . PjRtt109 and PcRtt109 showed similar low micromolar sensitivities to two reported small-molecule HAT inhibitors in vitro . Together, these results demonstrate that PjRtt109 is a functional Rtt109 HAT, and they support the development of anti- Pneumocystis agents directed at Rtt109-catalyzed histone acetylation as a novel therapeutic target for human PcP.
Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma
Smeltzer, Jacob P., Jones, Jason M. , Ziesmer, Steven C., Grote, Deanna M., Xiu, Bing, Ristow, Kay M., Nowakowski, Grzegorz S. , Feldman, Andrew L. , Cerhan, James R. , Novak, Anne J. , Ansell, Stephen M. , Yang, Zhi Zhang , Feldman, Andrew L , Cerhan, James R

Mayo Clinic

Clinical Cancer Research | April 12, 2014 | Volume: 20 | Issue: 11 | Pages: 2862-2872

10.1158/1078-0432.ccr-13-2367 | PMID 24727328 Get It

Abstract Purpose: Transformation of follicular lymphoma is a critical event associated with a poor prognosis. The role of the tumor microenvironment in previous transformation studies has yielded conflicting results. Experimental Design: To define cell subtypes associated with transformation, we examined tissue specimens at diagnosis from patients with follicular lymphoma that later transformed and, using immunohistochemistry (IHC), stained for CD68, CD11c, CD21, CXCL13, FOXP3, PD1, and CD14. Cell content and the pattern of expression were evaluated. Those identified as significantly associated with time to transformation (TTT) and overall survival (OS) were further characterized by flow cytometry and multicolor IHC. Results: Of note, 58 patients were analyzed with median TTT of 4.7 years. The pattern of PD1+ and CD14+ cells rather than the quantity of cells was predictive of clinical outcomes. On multivariate analysis, including the follicular lymphoma international prognostic index score, CD14+ cells localized in the follicle were associated with a shorter TTT (HR, 3.0; P = 0.004). PD1+ cells with diffuse staining were associated with a shorter TTT (HR, 1.9; P = 0.045) and inferior OS (HR, 2.5; P = 0.012). Multicolor IHC and flow cytometry identified CD14+ cells as follicular dendritic cells (FDC), whereas PD1+ cells represented two separate populations, TFH and exhausted T cells. Conclusion: These results identify the presence of PD1+ T cells and CD14+ FDC as independent predictors of transformation in follicular lymphoma. Clin Cancer Res; 20(11); 2862–72. ©2014 AACR.
Anatomy of hepatic arteriolo‐portal venular shunts evaluated by 3D micro‐CT imaging
Kline, Timothy L. , Anderson, Jill , Vercnocke, Andrew J. , Jorgensen, Steven M., Ritman, Erik L., Knudsen, Bruce E.

Mayo Clinic

Journal of Anatomy | March 31, 2014 | Volume: 224 | Issue: 6 | Pages: 724-731

10.1111/joa.12178 | PMID 24684343 Get It

AbstractThe liver differs from other organs in that two vascular systems deliver its blood – the hepatic artery and the portal vein. However, how the two systems interact is not fully understood. We therefore studied the microvascular geometry of rat liver hepatic artery and portal vein injected with the contrast polymer Microfil®. Intact isolated rat livers were imaged by micro‐CT and anatomic evidence for hepatic arteriolo‐portal venular shunts occurring between hepatic artery and portal vein branches was found. Simulations were performed to rule out the possibility of the observed shunts being artifacts resulting from image blurring. In addition, in the case of specimens where only the portal vein was injected, only the portal vein was opacified, whereas in hepatic artery injections, both the hepatic artery and portal vein were opacified. We conclude that mixing of the hepatic artery and portal vein blood can occur proximal to the sinusoidal level, and that the hepatic arteriolo‐portal venular shunts may function as a one‐way valve‐like mechanism, allowing flow only from the hepatic artery to the portal vein (and not the other way around).
P4‐335: Integrating whole‐exome sequencing and imaging genetics to identify single‐nucleotide variants associated with rate of hippocampal neurodegeneration in APOE‐ε3/ε3 males with mild cognitive impairment
Corneveaux, Jason J., Lin, Hai , Inlow, Mark , Siniard, Asheley, Reiman, Rebecca, Weiner, Michael W. , Huentelman, Matthew J. , (ADNI), Alzheimer's Disease Neuroimaging Initiative, Nho, Kwangsik T. , Kim, Sungeun , Risacher, Shannon L. , Shen, Li , Liu, Yunlong , Foroud, Tatiana , Green, Robert C. , Jack, Clifford R. , Saykin, Andrew J. , (ADNI), Alzheimer's Disease Neuroimaging Initiative

Mayo Clinic

Alzheimer's & Dementia | March 29, 2014 | Volume: 8 | Issue: 4S_Part_21 | Pages: No page available

10.1016/j.jalz.2013.08.116 Get It

Multidisciplinary Consensus on Assessment of Unruptured Intracranial Aneurysms
Etminan, Nima , Beseoglu, Kerim , Barrow, Daniel L. , Bederson, Joshua B. , Brown, Robert D., Connolly, E. Sander , Derdeyn, Colin P. , Hänggi, Daniel , Hasan, David , Juvela, Seppo , Kasuya, Hidetoshi , Kirkpatrick, Peter J., Knuckey, Neville W., Koivisto, Timo , Lawton, Michael T. , LeRoux, Peter D. , McDougall, Cameron G. , Mee, Edward , Molyneux, Andrew , Morgan, Michael K. , Mori, Kentaro , Morita, Akio , Nagahiro, Shinji, Pasqualin, A., Raabe, Andreas , Raymond, Jean , Rüfenacht, Daniel A. , Seifert, Volker , Spears, Julian , Steiger, Hans-Jakob, Steinmetz, Helmuth , Torner, James C., Vajkoczy, Peter , Wanke, Isabel , Wong, George Kwok Chu , Wong, John H. , Macdonald, R. Loch, Torner, James C. , Lanzino, Giuseppe , Mocco, J , Murayama, Yuichi , Rinkel, Gabriël J.E. , Morita, Akio , Barrow, Daniel L , Derdeyn, Colin P

Mayo Clinic

Stroke | March 25, 2014 | Volume: 45 | Issue: 5 | Pages: 1523-1530

10.1161/strokeaha.114.004519 | PMID 24668202 Get It

Background and Purpose— To address the increasing need to counsel patients about treatment indications for unruptured intracranial aneurysms (UIA), we endeavored to develop a consensus on assessment of UIAs among a group of specialists from diverse fields involved in research and treatment of UIAs. Methods— After composition of the research group, a Delphi consensus was initiated to identify and rate all features, which may be relevant to assess UIAs and their treatment by using ranking scales and analysis of inter-rater agreement (IRA) for each factor. IRA was categorized as very high, high, moderate, or low. Results— Ultimately, 39 specialists from 4 specialties agreed (high or very high IRAs) on the following key factors for or against UIA treatment decisions: (1) patient age, life expectancy, and comorbid diseases; (2) previous subarachnoid hemorrhage from a different aneurysm, family history for UIA or subarachnoid hemorrhage, nicotine use; (3) UIA size, location, and lobulation; (4) UIA growth or de novo formation on serial imaging; (5) clinical symptoms (cranial nerve deficit, mass effect, and thromboembolic events from UIAs); and (6) risk factors for UIA treatment (patient age and life expectancy, UIA size, and estimated risk of treatment). However, IRAs for features rated with low relevance were also generally low, which underlined the existing controversy about the natural history of UIAs. Conclusions— Our results highlight that neurovascular specialists currently consider many features as important when evaluating UIAs but also highlight that the appreciation of natural history of UIAs remains uncertain, even within a group of highly informed individuals.
Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug‐Induced Liver Injury Network (DILIN)
Hayashi, Paul H. , Chalasani, Naga , Davern, Timothy J., Talwalkar, Jayant A., Reddy, K. Rajender , Stolz, Andrew , Hoofnagle, Jay H., Barnhart, Huiman Xie , Fontana, Robert J. , Rockey, Don C.

Mayo Clinic

Liver International | March 25, 2014 | Volume: 35 | Issue: 5 | Pages: 1623-1632

10.1111/liv.12540 | PMID 24661785 Get It

AbstractBackground & AimsBecause of the lack of objective tests to diagnose drug‐induced liver injury (DILI), causality assessment is a matter of debate. Expert opinion is often used in research and industry, but its test–retest reliability is unknown. To determine the test–retest reliability of the expert opinion process used by the Drug‐Induced Liver Injury Network (DILIN).MethodsThree DILIN hepatologists adjudicate suspected hepatotoxicity cases to one of five categories representing levels of likelihood of DILI. Adjudication is based on retrospective assessment of gathered case data that include prospective follow‐up information. One hundred randomly selected DILIN cases were re‐assessed using the same processes for initial assessment but by three different reviewers in 92% of cases.ResultsThe median time between assessments was 938 days (range 140–2352). Thirty‐one cases involved >1 agent. Weighted kappa statistics for overall case and individual agent category agreement were 0.60 (95% CI: 0.50–0.71) and 0.60 (0.52–0.68) respectively. Overall case adjudications were within one category of each other 93% of the time, while 5% differed by two categories and 2% differed by three categories. Fourteen per cent crossed the 50% threshold of likelihood owing to competing diagnoses or atypical timing between drug exposure and injury.ConclusionsThe DILIN expert opinion causality assessment method has moderate interobserver reliability but very good agreement within one category. A small but important proportion of cases could not be reliably diagnosed as ≥50% likely to be DILI.
A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease
Investigators, The Parkinson Study Group QE3, Beal, M. Flint, Oakes, David , Shoulson, Ira , Henchcliffe, Claire , Galpern, Wendy R., Haas, Richard , Juncos, Jorge L., Nutt, John G. , Voss, Tiffini, Ravina, Bernard, Shults, Clifford M., Helles, Karen, Snively, Victoria, Lew, Mark, Griebner, Brian, Watts, Arthur, Gao, Shan , Pourcher, Emmanuelle, Bond, Louisette, Kompoliti, Katie , Sia, Cherissa, Jog, Mandar , Sultana, Munira , Kurlan, Roger, Richard, Irene Hegeman, Deeley, Cheryl, Waters, Cheryl , Figueroa, Angel, Arkun, Ani, Brodsky, Matthew , Ondo, William G. , Hunter, Christine , Jimenez‐Shahed, Joohi , Palao, Alicia, Miyasaki, Janis M. , So, Julie , Tetrud, James W., Reys, Liza, Singer, Carlos , Blenke, Anita, Russell, David , Cotto, Candace, Lannon, Margaret C., Drasby, Edward, Kumar, Rajeev , Subramanian, Thyagarajan , Ford, Donna Stuppy, Grimes, David A. , Côté, Diane , Conway, Jennifer, Siderowf, Andrew , Evatt, Marian L., Sommerfeld, Barbara, Lieberman, Abraham, Okun, Michael S. , Rodriguez, Ramon L. , Merritt, Stacy, Swartz, Camille, Martin, W. R. Wayne , King, Pamela, Stover, Natividad , Guthrie, Stephanie, Watts, Ray L., Fernandez, Hubert H. , Winters, Adrienna, Dawson, Ted M. , Dunlop, Becky, Feigin, Andrew, Shannon, Barbara , Nirenberg, Melissa J. , Ogg, Mattson , Ellias, Samuel A., Thomas, Cathi-Ann, Frei, Karen , Bódis-Wollner, Iván , Glazman, Sofya, Mayer, Thomas A. , Hauser, Robert A. , Langhammer, April, Ranawaya, Ranjit, Derwent, Lorelei, Farrow, Buff, Prakash, Rajan , Litvan, Irene , Robinson, Annette, Sahay, Alok , Gartner, Maureen, Markind, Samuel, Pelikan, Melisa, Hartlein, Johanna M, Molho, Eric , Evans, Sharon, Duffy, Amy, Lind, Marlene, Elmer, Lawrence , Davis, Kathy, Spears, Julia, Leehey, Maureen A. , Hermanowicz, Neal , Niswonger, Shari, Shill, Holly A. , Obradov, Sanja, Rajput, Alex, Cowper, Marilyn, Lessig, Stephanie, Fontaine, Deborah, Zadikoff, Cindy , Williams, Karen, Blindauer, Karen, Bergholte, Jo, Propsom, Clara Schindler, Stacy, Mark, Field, Joanne, Mihaila, Dragos, Chilton, Mark, Uc, Ergun Y., Sieren, Jeri, Simon, David K. , Kraics, Lauren, Silver, Althea, Boyd, James T. , Hamill, Robert W., Ingvoldstad, Christopher T., Young, Jennifer , Thomas, Karen, Kostyk, Sandra K. , Wojcieszek, Joanne, Pfeiffer, Ronald F. , Panisset, Michel , Beland, Monica, Reich, Stephen G. , Cines, Michelle, Zappala, Nancy, Rivest, J., Zweig, Richard M., Lumina, L. Pepper, Hilliard, Colette Lynn, Grill, Stephen , Kellermann, Marye, Tuite, Paul , Rolandelli, Susan, Kang, Un Jung , Young, Joan, Rao, Jayaraman, Cook, Maureen, Severt, Lawrence, Boyar, Karyn, Scott, Ingrid U. , Investigators, The Parkinson Study Group QE3, Beal, M. Flint , Agarwal, Pinky , Cole, Linda C. , Smith, Katharine , Friedman, Joseph H. , Zhang, Lin , Ahmed, Anwar E. , Mari, Zoltan K. , Pahwa, Rajesh , Sethi, Kapil D. , Hinson, Vanessa K. , Perlmutter, Joel S. , Adler, Charles H. , Wilson, Stephanie M. G. , Song, David , Williams, Karen, Uc, Ergun Y., Okun, Michael S , Litvan, Irene , Hauser, Robert A , Jimenez-Shahed, Joohi

Mayo Clinic

JAMA Neurology | March 25, 2014 | Volume: 71 | Issue: 5 | Pages: 543

10.1001/jamaneurol.2014.131 | PMID 24664227 Get It

Perioperative allogeneic nonleukoreduced blood transfusion and prostate cancer outcomes after radical prostatectomy
Yeoh, Tze Yeng, Scavonetto, Federica, Karnes, R. Jeffrey , Buskirk, Camille M. van , Hanson, Andrew C. , Schroeder, Darrell R. , Weingarten, Toby N. , Šprung, Juraj , Schroeder, Darrell

Mayo Clinic

Transfusion | March 24, 2014 | Volume: 54 | Issue: 9 | Pages: 2175-2181

10.1111/trf.12595 | PMID 24660833 Get It

BackgroundAllogeneic blood transfusion induces immunosuppression, and concern has been raised that it may increase propensity for cancer recurrence; however, these effects have not been confirmed. We examined the association of perioperative transfusion of allogeneic blood long‐term oncologic outcomes in patients with prostate cancer who underwent prostatectomy.Study Design and MethodsWe reviewed medical records of patients who underwent radical prostatectomy between 1991 and 2005 and received allogeneic nonleukoreduced blood. Each transfused patient was matched to two controls who did not receive blood: matching included age, surgical year, prostate‐specific antigen level, pathologic tumor stages, pathologic Gleason scores, and anesthetic type. Primary outcome was systemic tumor progression, with secondary outcomes of prostate cancer death and all‐cause mortality. Stratified proportional hazards regression analysis was used to assess differences in outcomes between the transfused and nontransfused group.ResultsA total of 379 prostatectomy patients who were transfused and 758 nontransfused controls were followed for 9.4 and 10.2 years (median), respectively. In a multivariable analysis that took into account the matched study design and adjusted for positive surgical margins and adjuvant therapies, the use of allogeneic blood was not associated with systemic tumor progression (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.39‐1.99; p = 0.76), prostate cancer–specific death (HR, 1.69; 95% CI, 0.44 to 6.48; p = 0.44), or all‐cause death (HR, 1.20; 95% CI, 0.87 to 1.67; p = 0.27).ConclusionsWhen adjusted for clinicopathologic and procedural variables transfusion of allogeneic blood was not associated with systemic tumor progression and survival outcomes.